← Back to All US Stocks

CCRN Stock Analysis - CROSS COUNTRY HEALTHCARE INC AI Rating

CCRN Nasdaq Services-Help Supply Services DE CIK: 0001141103
Recently Updated • Analysis: Mar 22, 2026 • SEC Data: 2025-12-31
AI Rating
SELL
78% Confidence

📊 CCRN Key Takeaways

Revenue: $1.1B
Net Margin: -9.0%
Free Cash Flow: $40.1M
Current Ratio: 3.78x
Debt/Equity: 0.00x
EPS: $-2.93
AI Rating: SELL with 78% confidence

Investment Thesis

Cross Country Healthcare faces severe operational distress with massive revenue contraction of 21.6% YoY and deteriorating profitability, including a net loss of $94.9M and negative operating income of $84.4M. While the company maintains adequate liquidity with a 3.78x current ratio and zero long-term debt, operational performance has dramatically worsened and is unsustainable without significant turnaround efforts.

CCRN Strengths

  • + Strong liquidity position with $108.7M cash and 3.78x current ratio
  • + Zero long-term debt provides financial flexibility
  • + Positive free cash flow of $40.1M despite operational losses
  • + Substantial asset base of $449M to support restructuring

CCRN Risks

  • ! Revenue declined 21.6% YoY with operating income of -$84.4M indicating severe business headwinds
  • ! Net margin of -9.0% and negative ROE of -29.4% show the business is destroying shareholder value
  • ! Gross margin of only 4.6% provides minimal buffer for operational expenses and leaves no room for error
  • ! Operating losses despite positive FCF suggest unsustainable accounting quality and potential working capital management concerns

Key Metrics to Watch

CCRN Financial Metrics

Revenue
$1.1B
Net Income
$-94.9M
EPS (Diluted)
$-2.93
Free Cash Flow
$40.1M
Total Assets
$449.0M
Cash Position
$108.7M

💡 AI Analyst Insight

The relatively thin 3.8% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.78x current ratio provides a solid financial cushion.

CCRN Profitability Ratios

Gross Margin 4.6%
Operating Margin -8.0%
Net Margin -9.0%
ROE -29.4%
ROA -21.1%
FCF Margin 3.8%

CCRN vs Default Sector

How CROSS COUNTRY HEALTHCARE INC compares to Default sector averages

Net Margin
CCRN -9.0%
vs
Sector Avg 12.0%
CCRN Sector
ROE
CCRN -29.4%
vs
Sector Avg 15.0%
CCRN Sector
Current Ratio
CCRN 3.8x
vs
Sector Avg 1.8x
CCRN Sector
Debt/Equity
CCRN 0.0x
vs
Sector Avg 0.7x
CCRN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CCRN Balance Sheet & Liquidity

Current Ratio
3.78x
Quick Ratio
3.78x
Debt/Equity
0.00x
Debt/Assets
28.1%
Interest Coverage
-182.71x
Long-term Debt
$0.0

CCRN 5-Year Financial Trend

CCRN 5-year financial data: Year 2021: Revenue $1.7B, Net Income -$57.7M, EPS $-1.61. Year 2022: Revenue $2.8B, Net Income -$13.0M, EPS $-0.36. Year 2023: Revenue $2.8B, Net Income $132.0M, EPS $3.53. Year 2024: Revenue $2.8B, Net Income $186.0M, EPS $4.95. Year 2025: Revenue $2.0B, Net Income $72.6M, EPS $2.05.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: CROSS COUNTRY HEALTHCARE INC's revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.05 reflects profitable operations.

CCRN Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.8%
Free cash flow / Revenue

CCRN Quarterly Performance

Quarterly financial performance data for CROSS COUNTRY HEALTHCARE INC including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $250.1M $2.6M $0.08
Q2 2025 $274.1M -$6.7M $-0.20
Q1 2025 $293.4M -$490.0K $-0.02
Q3 2024 $315.1M $2.6M $0.08
Q2 2024 $339.8M -$13.4M $-0.39
Q1 2024 $379.2M $2.7M $0.08
Q3 2023 $442.3M $12.8M $0.36
Q2 2023 $540.7M $21.3M $0.60

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CCRN Capital Allocation

Operating Cash Flow
$48.3M
Cash generated from operations
Stock Buybacks
$6.8M
Shares repurchased (TTM)
Capital Expenditures
$8.2M
Investment in assets
Dividends
None
No dividend program

CCRN SEC Filings

Access official SEC EDGAR filings for CROSS COUNTRY HEALTHCARE INC (CIK: 0001141103)

📋 Recent SEC Filings

Date Form Document Action
Mar 17, 2026 8-K cc8k.htm View →
Mar 12, 2026 4 xslF345X05/form4.xml View →
Mar 10, 2026 8-K cc8k.htm View →
Mar 9, 2026 10-K ccrn-20251231.htm View →
Mar 4, 2026 8-K ccrn-20260304.htm View →

Frequently Asked Questions about CCRN

What is the AI rating for CCRN?

CROSS COUNTRY HEALTHCARE INC (CCRN) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CCRN's key strengths?

Strong liquidity position with $108.7M cash and 3.78x current ratio. Zero long-term debt provides financial flexibility.

What are the risks of investing in CCRN?

Revenue declined 21.6% YoY with operating income of -$84.4M indicating severe business headwinds. Net margin of -9.0% and negative ROE of -29.4% show the business is destroying shareholder value.

What is CCRN's revenue and growth?

CROSS COUNTRY HEALTHCARE INC reported revenue of $1.1B.

Does CCRN pay dividends?

CROSS COUNTRY HEALTHCARE INC does not currently pay dividends.

Where can I find CCRN SEC filings?

Official SEC filings for CROSS COUNTRY HEALTHCARE INC (CIK: 0001141103) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CCRN's EPS?

CROSS COUNTRY HEALTHCARE INC has a diluted EPS of $-2.93.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-12-31 | Powered by Claude AI